Innovations Into Success Summer 2016 | Page 47

Our decision to become BioCity tenants was and keeps continuing to be an excellent decision Peter Ridgway – Reach Separations
State of the art laboratories
accelerator programmes but they are redesigned to suit the needs of life science and healthcare innovations .
Finance Access to finance is a key challenge for high tech companies and yet intelligent investing in these businesses can create fantastic returns . BioCity Group can help companies raise money through established connections with grant awarding bodies and early stage investors , but it can also invest through its own funds and through funds it manages for others , such as the Alderley Park Ventures fund .
The early stage knowledge of the team and opportunity ( preinvestment ) combined with the regular contact and help offered at a BioCity Group location ( post-investment ) helps to buck the trend of performance of early stage venture capital . To date , the BioCity Group has an investment return of 6.8 times .
Innovation Community There are more than 200 companies based at the five locations employing over 1,000 employees . The site teams work hard to ensure the effective networking and integration of the various companies and as a result many collaborate and work with each other .
However , the community extends far beyond the boundaries of the sites . BioCity Group has established relationships with many universities , patient groups , healthcare providers and NHS departments as well as the innovation and corporate venturing teams in larger pharmaceutical and healthcare companies .
These connections offer the opportunity to inform and accelerate company development but they also offer community members the chance to influence and shape the type of innovative new products and services being developed .
These core components have helped create clear success . There is a 12 year 91 % survival rate of all companies started at the Nottingham site and occupancy across all locations has grown year on year .
The rapid development of pharmaceutical contract research organisations ( CROs ) is being led by fast growing companies such as Sygnature Discovery and Reach Separations . The IP based ventures , such as Haemostatix , Monica Healthcare , Blueberry Therapeutics and Locate Therapeutics , have accumulatively raised over £ 50m of venture capital and are set to provide healthy returns as the macro-economic conditions improve .
To join the success story either as a company , an investor or as a member of the wider community please get in touch .
e : enquiries @ biocity . co . uk
Locations BioCity , Nottingham is based in the Creative Quarter of the city . It is the first BioCity site and now home to over 70 companies . The 120,000 sq ft is spread across 3 buildings and construction of a new building is well advanced . BioCity , Nottingham is home to one of the largest collections of pharmaceutical contract research organisations in the UK .
BioHub is based on the AstraZeneca site at Alderley Park , Cheshire . The 86,000 sq ft dedicated to the BioHub is part of a much larger campus , now owned by Manchester Science Park , that also provides substantial grow on space .
MediCity Nottingham is based in the Enterprise Zone on the AllianceBoots campus . MediCity Nottingham occupies 100,000sq ft in the iconic art-deco D6 building . The building also has impressive conferencing facilities and hosts big events connected to health , beauty and innovation .
BioCity , Scotland and MediCity , Scotland are both based at the former MSD research facility at Newhouse , 13 miles outside Glasgow and 35 miles from Edinburgh . The 130,000 sq ft at the site also boasts specialist facilities such as the compound management library and GMP storage and archiving .
England • Full Member UKSPA Directory 2016 / 17 45